静脉血栓栓塞-话题@MedSci

#静脉血栓栓塞#

15篇内容 | 2132人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2188880, encodeId=940b218888072, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a> <a href='/topic/show?id=be8384e20c0' target=_blank style='color:#2F92EE;'>#脑出血患者#</a>, objectTitle=神经外科ICU脑出血患者静脉血栓栓塞预防与管理的证据总结, objectType=article, longId=814463, objectId=17c6814463a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016400776_4754896.jpg, objectUrl=/article/show_article.do?id=17c6814463a6, replyNumber=0, likeNumber=11, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=17c6814463a6, moduleTitle=神经外科ICU脑出血患者静脉血栓栓塞预防与管理的证据总结, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c6814463a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185774, encodeId=83632185e74c0, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a> <a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, objectTitle=静脉血栓栓塞症抗凝治疗相关出血风险预测模型研究进展, objectType=article, longId=812219, objectId=7235812219b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240131/523e4858a56d4fec85b15a292a00b385.jpg, objectUrl=/article/show_article.do?id=7235812219b3, replyNumber=0, likeNumber=35, createdTime=2024-02-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=7235812219b3, moduleTitle=静脉血栓栓塞症抗凝治疗相关出血风险预测模型研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7235812219b3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174512, encodeId=493e21e451250, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a> 静脉血栓栓塞（VTE）是一种常见的心血管疾病，其发病率逐年增加。肥胖被确认为VTE的危险因素，而全球范围内肥胖的流行率也在快速上升。肥胖定义为体质指数（BMI）达到30 kg/m2或更高。过去的研究已经揭示肥胖与VTE之间的紧密关系，但在肥胖患者中使用直接口服抗凝药（DOACs）的安全性和有效性方面的证据相对有限。, objectTitle=静脉血栓栓塞, objectType=topic, longId=99179, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=15, createdTime=2023-12-12, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2174211, encodeId=f6b721e4211ee, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a> <a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>, objectTitle=Thromb Res:直接作用口服抗凝剂推荐剂量对肥胖与正常体重静脉血栓栓塞患者的现实生活结果, objectType=article, longId=804549, objectId=0fe08045491c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024236648_4754896.jpeg, objectUrl=/article/show_article.do?id=0fe08045491c, replyNumber=0, likeNumber=28, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0fe08045491c, moduleTitle=Thromb Res:直接作用口服抗凝剂推荐剂量对肥胖与正常体重静脉血栓栓塞患者的现实生活结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe08045491c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2166109, encodeId=27ab216610922, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a> , objectTitle=成人烧伤患者静脉血栓栓塞症预防的证据总结, objectType=guider, longId=25178, objectId=8ea5d1c00325395d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=8ea5d1c00325395d, replyNumber=0, likeNumber=42, createdTime=2023-11-01, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8ea5d1c00325395d, moduleTitle=成人烧伤患者静脉血栓栓塞症预防的证据总结, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=8ea5d1c00325395d)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2118411, encodeId=e37b211841162, content=<a href='/topic/show?id=3522389386f' target=_blank style='color:#2F92EE;'>#同型半胱氨酸#</a>与<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>相关, objectTitle=ATVB：同型半胱氨酸与静脉血栓栓塞相关, objectType=article, longId=212214, objectId=62b521221494, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202162/1622647569826_1739456.png, objectUrl=/article/show_article.do?id=62b521221494, replyNumber=0, likeNumber=51, createdTime=2023-03-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=62b521221494, moduleTitle=ATVB：同型半胱氨酸与静脉血栓栓塞相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62b521221494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2116674, encodeId=7f0521166e4bf, content=<a href='/topic/show?id=69bbe11620e' target=_blank style='color:#2F92EE;'>#痛风#</a>发作的<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>的风险, objectTitle=A&R：伴有痛风发作的静脉血栓栓塞的风险, objectType=article, longId=760501, objectId=dc2be60501e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230223/1677083414906_5610093.png, objectUrl=/article/show_article.do?id=dc2be60501e4, replyNumber=0, likeNumber=60, createdTime=2023-02-27, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dc2be60501e4, moduleTitle=A&R：伴有痛风发作的静脉血栓栓塞的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc2be60501e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, objectTitle=抗凝药物治疗静脉血栓栓塞症争议与共识, objectType=guider, longId=15926, objectId=cb73f1c002328e6f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=cb73f1c002328e6f, replyNumber=0, likeNumber=66, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb73f1c002328e6f, moduleTitle=抗凝药物治疗静脉血栓栓塞症争议与共识, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=cb73f1c002328e6f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241572, encodeId=093a12415e2e2, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=64cf9011550' target=_blank style='color:#2F92EE;'>#补体#</a>, objectTitle=ATVB：补体激活酶MASP-2水平与静脉血栓栓塞的风险相关, objectType=article, longId=733311, objectId=d355e3331156, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220726/1658819607463_1739456.jpg, objectUrl=/article/show_article.do?id=d355e3331156, replyNumber=0, likeNumber=76, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d355e3331156, moduleTitle=ATVB：补体激活酶MASP-2水平与静脉血栓栓塞的风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d355e3331156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241718, encodeId=2c181241e18b8, content=<a href='/topic/show?id=f5f610462e09' target=_blank style='color:#2F92EE;'>#Milvexian#</a>预防<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>，这是一种新型的<a href='/topic/show?id=8516552389b' target=_blank style='color:#2F92EE;'>#抗凝药#</a>物，未来前景可期！, objectTitle=NEJM：Milvexian用于预防静脉血栓栓塞, objectType=article, longId=221432, objectId=30622214323d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021122/1638403448315_1739456.jpg, objectUrl=/article/show_article.do?id=30622214323d, replyNumber=0, likeNumber=67, createdTime=2022-08-29, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30622214323d, moduleTitle=NEJM：Milvexian用于预防静脉血栓栓塞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30622214323d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241571, encodeId=105612415e134, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>, objectTitle=J Thromb Haemost：COVID-19疫苗接种后静脉血栓栓塞的风险, objectType=article, longId=724198, objectId=82ace2419885, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220413/1649820895319_1739456.jpg, objectUrl=/article/show_article.do?id=82ace2419885, replyNumber=0, likeNumber=73, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82ace2419885, moduleTitle=J Thromb Haemost：COVID-19疫苗接种后静脉血栓栓塞的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82ace2419885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241570, encodeId=293612415e026, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>, objectTitle=JAHA：静脉血栓栓塞的家族性分离, objectType=article, longId=292187, objectId=4ed129218ef5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211217/1639750285474_1739456.jpg, objectUrl=/article/show_article.do?id=4ed129218ef5, replyNumber=0, likeNumber=60, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ed129218ef5, moduleTitle=JAHA：静脉血栓栓塞的家族性分离, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ed129218ef5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241569, encodeId=e44b12415695e, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=3c531016e571' target=_blank style='color:#2F92EE;'>#骨折#</a>, objectTitle=2021年版《亚太膝关节和髋关节置换术和髋部骨折手术静脉血栓栓塞共识：静脉血栓栓塞症的药物预防》解读, objectType=guider, longId=16895, objectId=367a71c002a25640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=367a71c002a25640, replyNumber=0, likeNumber=89, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367a71c002a25640, moduleTitle=2021年版《亚太膝关节和髋关节置换术和髋部骨折手术静脉血栓栓塞共识：静脉血栓栓塞症的药物预防》解读, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=367a71c002a25640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241568, encodeId=94681241568df, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=ea866e8110d' target=_blank style='color:#2F92EE;'>#物理治疗#</a>, objectTitle=2022 APTA循证临床实践指南：物理治疗师在具有静脉血栓栓塞风险或被诊断为静脉血栓栓塞患者的管理中的作用, objectType=guider, longId=17931, objectId=b638a1c002529254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=b638a1c002529254, replyNumber=0, likeNumber=72, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b638a1c002529254, moduleTitle=2022 APTA循证临床实践指南：物理治疗师在具有静脉血栓栓塞风险或被诊断为静脉血栓栓塞患者的管理中的作用, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=b638a1c002529254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241567, encodeId=5759124156e31, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>, objectTitle=静脉血栓栓塞症国内外指南解读, objectType=guider, longId=16811, objectId=865af1c002a1e257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=865af1c002a1e257, replyNumber=0, likeNumber=90, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865af1c002a1e257, moduleTitle=静脉血栓栓塞症国内外指南解读, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=865af1c002a1e257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, objectTitle=J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较, objectType=article, longId=730707, objectId=45e3e3070798, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220627/1656343907354_1739456.jpg, objectUrl=/article/show_article.do?id=45e3e3070798, replyNumber=0, likeNumber=0, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e3e3070798, moduleTitle=J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e3e3070798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=916132, encodeId=ab6b91613292, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>, objectTitle=Crit Care：危重患者静脉血栓栓塞发生率、预后因素和结局, objectType=article, longId=205694, objectId=d1cd20569440, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021113/1610496706393_1739456.jpg, objectUrl=/article/show_article.do?id=d1cd20569440, replyNumber=0, likeNumber=168, createdTime=2021-01-13, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1cd20569440, moduleTitle=Crit Care：危重患者静脉血栓栓塞发生率、预后因素和结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1cd20569440)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904243, encodeId=4b7a90424351, content=<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>患者的<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=4a481855350' target=_blank style='color:#2F92EE;'>#VTE#</a>风险，这可能有多种原因，其一现在的治疗多是免疫治疗和靶向治疗，其二，患者的生存期延长，<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>患者多是<a href='/topic/show?id=ca06102195ec' target=_blank style='color:#2F92EE;'>#高凝状态#</a>，容易并发血栓。同时，如果适当的<a href='/topic/show?id=606b55e4466' target=_blank style='color:#2F92EE;'>#抗血小板#</a>和<a href='/topic/show?id=353b55219b8' target=_blank style='color:#2F92EE;'>#抗凝#</a>治疗，可能会有利于改善<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>，有利于治疗。, objectTitle=Blood：1997年-2017年癌症患者的静脉血栓栓塞风险变化, objectType=article, longId=203916, objectId=4d2220391612, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/type2diabetes-s18-plaque-in-artery.jpg, objectUrl=/article/show_article.do?id=4d2220391612, replyNumber=0, likeNumber=282, createdTime=2020-12-02, rootId=0, userName=lifefamily@163, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2220391612, moduleTitle=Blood：1997年-2017年癌症患者的静脉血栓栓塞风险变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d2220391612)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#静脉血栓栓塞# #脑出血患者#

神经外科ICU脑出血患者静脉血栓栓塞预防与管理的证据总结

2024-02-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#静脉血栓栓塞# #预测模型#

静脉血栓栓塞症抗凝治疗相关出血风险预测模型研究进展

2024-02-04发表于加利福尼亚

yangchou (审核中...)

前往app查看评论内容

全文收起 #静脉血栓栓塞# 静脉血栓栓塞（VTE）是一种常见的心血管疾病，其发病率逐年增加。肥胖被确认为VTE的危险因素，而全球范围内肥胖的流行率也在快速上升。肥胖定义为体质指数（BMI）达到30 kg/m2或更高。过去的研究已经揭示肥胖与VTE之间的紧密关系，但在肥胖患者中使用直接口服抗凝药（DOACs）的安全性和有效性方面的证据相对有限。

2023-12-12发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#口服抗凝剂# #静脉血栓栓塞#

Thromb Res:直接作用口服抗凝剂推荐剂量对肥胖与正常体重静脉血栓栓塞患者的现实生活结果

2023-12-11发表于上海

(审核中...)

前往app查看评论内容

#静脉血栓栓塞#

成人烧伤患者静脉血栓栓塞症预防的证据总结

2023-11-01发表于上海

showtest (审核中...)

前往app查看评论内容

#同型半胱氨酸#与#静脉血栓栓塞#相关

ATVB：同型半胱氨酸与静脉血栓栓塞相关

2023-03-09发表于上海

showtest (审核中...)

前往app查看评论内容

#痛风#发作的#静脉血栓栓塞#的风险

A&R：伴有痛风发作的静脉血栓栓塞的风险

2023-02-27发表于上海

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞#与#抗凝药物#

抗凝药物治疗静脉血栓栓塞症争议与共识

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞##补体#

ATVB：补体激活酶MASP-2水平与静脉血栓栓塞的风险相关

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#Milvexian#预防#静脉血栓栓塞#，这是一种新型的#抗凝药#物，未来前景可期！

NEJM：Milvexian用于预防静脉血栓栓塞

2022-08-29

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞#

J Thromb Haemost：COVID-19疫苗接种后静脉血栓栓塞的风险

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞#

JAHA：静脉血栓栓塞的家族性分离

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞##骨折#

2021年版《亚太膝关节和髋关节置换术和髋部骨折手术静脉血栓栓塞共识：静脉血栓栓塞症的药物预防》解读

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞##物理治疗#

2022 APTA循证临床实践指南：物理治疗师在具有静脉血栓栓塞风险或被诊断为静脉血栓栓塞患者的管理中的作用

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#静脉血栓栓塞#

静脉血栓栓塞症国内外指南解读

2022-08-28

循证小兵 (审核中...)

前往app查看评论内容

#艾多沙班#、#利伐沙班#和#阿哌沙班#在#静脉血栓栓塞##血栓栓塞#

J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较

2022-08-28

zb1235672 (审核中...)

前往app查看评论内容

#静脉血栓栓塞#

Crit Care：危重患者静脉血栓栓塞发生率、预后因素和结局

2021-01-13

lifefamily@163 (审核中...)

前往app查看评论内容

#癌症#患者的#静脉血栓栓塞##VTE#风险，这可能有多种原因，其一现在的治疗多是免疫治疗和靶向治疗，其二，患者的生存期延长，#肿瘤#患者多是#高凝状态#，容易并发血栓。同时，如果适当的#抗血小板#和#抗凝#治疗，可能会有利于改善#肿瘤微环境#，有利于治疗。

Blood：1997年-2017年癌症患者的静脉血栓栓塞风险变化

2020-12-02

科室
- - 订阅+
  - 更多科室
工具
服务